Update: Cypress BioScience

Decided last week to get out of this position.   The stock had a nice run from low 7’s to low 9’s and I was able to get out for a 30% gain. 

Reasons I got out:

1.  I was having mixed results with Savella, based on initial patients,  tolerability appeared worse than Cymbalta.  Some patients did very well but many had nausea or other side effects.  I will still use Savella but probably not as frequently.

2.  Though Savella sales are continuing to grow, they are not exploding (data from Yahoo MB but looks like source is reliable).

3.  Managed care will likely put more restrictions on branded products as health care reform proceeds.

4.  I feel the market will generaly decline the second half of this year, though we may still have one final rush up.  Biotech and Pharma, already up a lot this year,  may not participate inthe final rush and I’m happy with 30%.   $13-$15 is certainly possible as sales escalate, but less likely than stagnation in 7-10 range if market declines later in year.